 Connection
Micol Rothman to Teriparatide
This is a "connection" page, showing publications Micol Rothman has written about Teriparatide.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.164 |
|
|
|
-
Graham T, Shoback DM, Abbott L, Lubitz S, Edelson G, Haider A, Ing SW, Rothman MS, Cusano NE, Zhao C, Ukena J, Schneider M, Sibley CT, Rubin MR. Early U.S. Real-World Treatment Patterns and Outcomes in Palopegteriparatide Treatment for Patients With Hypoparathyroidism. Endocr Pract. 2025 Dec; 31(12):1568-1575.
Score: 0.059
-
Kushchayeva Y, Kushchayev S, Dunn K, Pestun I, Rothman MS, Lewiecki EM. Bone Health ECHO Case Report: Significant Elevation in Bone Turnover Markers and Progression of Vertebral Fractures After Denosumab Discontinuation Followed by a PTH-Analog. J Clin Densitom. 2025 Jan-Mar; 28(1):101551.
Score: 0.057
-
McClung MR, Rothman MS, Lewiecki EM, Hanley DA, Harris ST, Miller PD, Kendler DL. The role of osteoanabolic agents in the management of patients with osteoporosis. Postgrad Med. 2022 Aug; 134(6):541-551.
Score: 0.048
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|